Preferred Label : Anti-SIRPa Monoclonal Antibody LM-101;
NCIt synonyms : Anti-SIRPalpha Monoclonal Antibody LM-101;
NCIt definition : A monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a),
with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic
activities. Upon administration, anti-SIRPa monoclonal antibody LM-101 targets and
binds to SIRPa, a cell surface protein expressed on macrophages, thereby blocking
the interaction between SIRPa and cluster of differentiation 47 (CD47) expressed on
tumor cells. This prevents CD47/SIRPa-mediated signaling and abrogates the CD47/SIRPa-mediated
inhibition of phagocytosis. This induces pro-phagocytic signaling mediated by the
binding of calreticulin (CRT), which is specifically expressed on the surface of tumor
cells, to low-density lipoprotein (LDL) receptor-related protein (LRP), expressed
on macrophages, and results in macrophage activation and the specific phagocytosis
of tumor cells. SIRPa, also known as tyrosine-protein phosphatase non-receptor type
substrate 1, mediates negative regulation of phagocytosis, mast cell activation and
dendritic cell activation. CD47, also called integrin-associated protein (IAP), is
a tumor-associated antigen (TAA) expressed on normal, healthy hematopoietic stem cells
(HSCs) and overexpressed on the surface of a variety of cancer cells. Expression of
CD47, and its interaction with SIRPa, leads to the inhibition of macrophage activation
and protects cancer cells from phagocytosis, which allows cancer cells to proliferate.;
Molecule name : LM-101; LM 101;
NCI Metathesaurus CUI : CL1913087;
Origin ID : C193461;
UMLS CUI : C5785770;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
